GlassScriptPhysician profile
Laura D Thomas
NPI 1184010456
$3,481.47
in general payments reported to CMS, 2019-2025
25 companies · $161 in 2025
The $161 reported for 2025 was less than what a typical Neurology With Special Qualifications In Child Neurology provider received nationally (typical 2025 total: $275).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $456 · 2022: $1,696 · 2023: $710 · 2024: $459 · 2025: $161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,195 · Travel and Lodging: $135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,194.72 |
| Travel and Lodging | $135.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $1,002.22 | 2022 | |
| Ucb, INC. | $958.15 | 2021-2025 | Briviact, Fintepla, Nayzilam |
| Jazz Pharmaceuticals INC. | $236.01 | 2022-2023 | |
| Neurelis, INC. | $205.73 | 2021-2025 | Valtoco |
| Eisai INC. | $138.68 | 2022-2023 | |
| Abbott Laboratories | $135.02 | 2024 | Cardiomems |
| Sumitomo Pharma America, INC. | $114.28 | 2023-2024 | Aptiom |
| Abbvie INC. | $89.56 | 2023-2025 | Botox |
| Zogenix INC. | $83.83 | 2021 | |
| Supernus Pharmaceuticals, INC. | $53.10 | 2021-2022 | |
| Catalyst Pharmaceuticals, INC. | $52.85 | 2023 | Fycompa |
| Sarepta Therapeutics, INC. | $51.81 | 2021-2023 | Elevidys |
| Mannkind Corporation | $45.85 | 2021 | |
| Immedica Pharma US, INC. | $45.39 | 2022 | |
| Biogen, INC. | $42.69 | 2025 | Spinraza |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $32.61 | 2022 | |
| Upsher-Smith Laboratories LLC | $27.68 | 2025 | |
| Novartis Gene Therapies, INC. (Fka Avexis, INC.) | $24.05 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $23.79 | 2022 | |
| Greenwich Biosciences, INC. | $22.97 | 2021 | |
| Neurocrine Biosciences, INC. | $21.51 | 2024 | Ingrezza |
| Sk Life Science, INC. | $20.82 | 2023 | |
| Amneal Pharmaceuticals LLC | $17.94 | 2023 | Lyvispah |
| Medtronic, INC. | $17.85 | 2022 | |
| Novartis Pharmaceuticals Corporation | $17.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.